CRDF | Cardiff Oncology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.20 - 4.67
52 Week Range	1.4100 - 6.42
Beta	2.01
Implied Volatility	130.83%
IV Rank	5.47%
Day's Volume	1,967,998
Average Volume	1,901,387
Shares Outstanding	66,518,400
Market Cap	283,368,384
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-07-27

Valuation
Profitability
Growth
Health
P/E Ratio	-4.48
Forward P/E Ratio	N/A
EPS	-0.95
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	31
Country	USA
Website	CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF's peers: RVPH, EFTR, PDSB, NAVB, RVPHW, EYEN, CGTX, RNAZ, KOD, SLS, NLSP, MREO, ARAV, DAWN, INAB, CUE, LTRN, GRCL, CGEM, BOLT, LYRA, AUTL

*Chart delayed

Analyzing fundamentals for CRDF we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see CRDF Fundamentals page.

Watching at CRDF technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CRDF Technicals page.